Project profile — Ancillary costs for donated COVID-19 vaccine doses procured via the COVAX Facility

This project aims to decrease COVID-19 related mortality and morbidity, especially for those experiencing marginalization or vulnerability, including women. The project also seeks to provide sufficient vaccine doses to immunize healthcare workers and most vulnerable groups in low- and lower-middle income countries. Project activity includes providing the necessary ancillaries to accompany COVID-19 vaccines declared surplus and donated by Canada to the COVAX Facility. Ancillaries may include freight, equipment, No Fault Compensation Scheme contribution, safety boxes, and syringes.

The expected outcomes of this project include: (1) decreased COVID-19 related mortality and morbidity of priority populations, especially for those experiencing marginalization or vulnerability, including women; and (2) increased vaccine doses to support immunization of healthcare workers and most vulnerable groups in low- and lower-middle-income countries.

Results achieved at the end of the project (December 2024) include: (1) provided the necessary ancillary supplies to accompany more than 652,800 COVID-19 vaccine doses donated by Canada through COVAX, and purchased through Canada’s Self Financing Participant agreement with COVAX; and (2) contributed to achieving 72% immunization coverage across older adults and 84% coverage amongst healthcare workers in AMC countries.